Helmholtz Gemeinschaft


Treatment choices and neuropsychological symptoms of a large cohort of early MS

PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Item Type:Article
Title:Treatment choices and neuropsychological symptoms of a large cohort of early MS
Creators Name:von Bismarck, O. and Dankowski, T. and Ambrosius, B. and Hessler, N. and Antony, Gi. and Ziegler, A. and Hoshi, M.M. and Aly, L. and Luessi, F. and Groppa, S. and Klotz, L. and Meuth, S.G. and Tackenberg, B. and Stoppe, M. and Then Bergh, F. and Tumani, H. and Kümpfel, T. and Stangel, M. and Heesen, C. and Wildemann, B. and Paul, F. and Bayas, A. and Warnke, C. and Weber, F. and Linker, R.A. and Ziemann, U. and Zettl, U.K. and Zipp, F. and Wiendl, H. and Hemmer, B. and Gold, R. and Salmen, A.
Abstract:OBJECTIVE: To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS. METHODS: The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms. RESULTS: Of 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06-40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0-2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0-377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively. CONCLUSION: Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients.
Source:Neurology Neuroimmunology & Neuroinflammation
Publisher:American Academy of Neurology
Page Range:e446
Date:1 May 2018
Official Publication:https://doi.org/10.1212/NXI.0000000000000446
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library